Last updated: February 20, 2026
What Does NDC 75907-0024 Refer To?
NDC 75907-0024 pertains to a specific drug product listed in the National Drug Code directory. Based on available data, this NDC corresponds to Evrysdi (risdiplam), a medication used to treat spinal muscular atrophy (SMA). It is manufactured by Roche.
Market Overview
Therapeutic Area: Spinal Muscular Atrophy (SMA)
SMA is a genetic neuromuscular disorder that causes muscle weakness and atrophy. The disease affects approximately 1 in 10,000 live births globally, with variable severity.
Market Size & Dynamics
| Parameter |
Data |
| Global SMA market (2022) |
Estimated at $600 million |
| CAGR (2022–2027) |
8.5% (Grand View Research) |
| Approved SMA treatments |
5 (including Evrysdi, Spinraza, Zolgensma) |
| SMA diagnosis rate |
Under 50% globally, due to limited screening |
Competition
Major competitors include:
- Spinraza (nusinersen): Biogen, launched 2016.
- Zolgensma (onasemnogene abeparvovec): Novartis, launched 2019.
- Evrysdi (risdiplam): Roche, launched 2020.
Evrysdi gained rapid adoption owing to its oral administration, advantageous over injectable competitors.
Key Market Drivers
- Expanding newborn screening programs.
- Increased approval for diverse age groups.
- Growing physician familiarity.
- Patent protections extending to 2030s for Evrysdi.
Market Penetration and Adoption
Uptake Timeline
| Time Since Launch |
Market Penetration |
Notes |
| Year 1 (2020) |
Initial launch in U.S. |
Focused on initial indications |
| Year 2 (2021) |
Increased prescriptions |
Expanded to Europe and Japan |
| Year 3 (2022) |
Broader indication expansion; dosage-based pricing |
Adoption accelerated |
Regional Considerations
- U.S.: Largest market, driven by favorable pricing policies, insurance coverage, and robust manufacturing scale.
- Europe: Growth hampered temporarily by regulatory delays but catching up.
- Asia-Pacific: Potential market, limited by high costs and regulatory approval processes.
Price Projections
Current Pricing
- List Price (U.S.): Approximately $340,000 per year per patient.
- Net Price: Estimated at 10–15% discounts due to negotiations, averaging ~$290,000–$310,000.
Historical Pricing Trends
| Year |
List Price |
Adjusted Price |
Notes |
| 2020 |
$340,000 |
Baseline |
Launch price |
| 2021 |
$340,000 |
No increase |
Stable price |
Short- to Medium-Term Projections (2023–2027)
| Year |
Predicted List Price |
Factors Influencing Price |
Notes |
| 2023 |
$340,000–$355,000 |
Inflation, manufacturing costs |
Slight increase expected |
| 2024 |
$355,000–$370,000 |
Expansion to new indications, higher demand |
Price adjustments linked to value-based contracting |
| 2025 |
$370,000–$385,000 |
Competitive pressure, biosimilar considerations |
Potential for negotiated discounts |
Long-Term Price Trends (Post-2027)
- Patent exclusivity until 2030s.
- Entry of biosimilars or generics expected from mid-2030s.
- Price reductions of 20–30% likely with biosimilar availability.
Revenue Projections
Assuming market penetration reaches 40,000 patients globally by 2027, with an average annual price of $350,000:
| Year |
Estimated Patients |
Revenue |
Notes |
| 2023 |
10,000 |
$3.5 billion |
Initial growth phase |
| 2025 |
25,000 |
$8.75 billion |
Market expansion |
| 2027 |
40,000 |
$14 billion |
Peak forecast |
This assumes stable pricing and no significant market disruptions.
Market Risks and Uncertainties
- Development of biosimilars reducing prices.
- Changes in regulatory policies affecting reimbursement.
- Entry of new therapies or combination treatments.
- Variability in global SMA diagnosis rates impacting market size.
Key Takeaways
- The SMA market is growing at approximately 8.5% annually, driven by increased diagnosis and treatment adoption.
- Evrysdi prices are approximately $340,000–$355,000 per year, with potential for incremental increases.
- Long-term price declines are probable with biosimilar competition expected by mid-2030s.
- Revenue potential depends on market penetration, with projections exceeding $14 billion globally by 2027.
- Market risks include biosimilar entry, regulatory shifts, and competition from emerging therapies.
FAQs
-
What factors influence the price of Evrysdi?
Manufacturing costs, demand, competition, insurance negotiations, and the value-based pricing landscape.
-
When are biosimilars for Evrysdi expected?
Likely mid-2030s, contingent on patent expiration and biosimilar development timelines.
-
How is the SMA market expected to evolve?
Continued growth driven by diagnosis expansion, new treatment indications, and higher demand.
-
What regional factors impact pricing and market share?
Reimbursement policies, regulatory approvals, healthcare infrastructure, and payer negotiations.
-
What are the main risks to revenue growth for Evrysdi?
Biosimilar competition, pricing pressures, regulatory hurdles, and new therapies reducing demand.
References
[1] Grand View Research. (2022). Spinal Muscular Atrophy Market Size, Share & Trends. Market Research Reports.
[2] FDA. (2020). Regulatory approval of Evrysdi. U.S. Food and Drug Administration.
[3] Roche. (2022). Evrysdi product information and market data.
[4] IQVIA. (2022). Prescription trends and market access data.
